Chemotherapy Induced Peripheral Neuropathy - Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment that can cause tingling, numbness, and pain in the hands and feet. CIPN is caused by damage to the nerves that send signals from the body to the brain.

Chemotherapy-induced neuropathy is caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib; these drugs cause different pathologic insults to neurons.

As per Global Insight services' assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Chemotherapy Induced Peripheral Neuropathy - pipeline landscape globally. Chemotherapy Induced Peripheral Neuropathy Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31233

Report Highlights
Global Insight Service's, Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline drugs. This report covers detailed insights on Chemotherapy Induced Peripheral Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chemotherapy Induced Peripheral Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Read more about Chemotherapy Induced Peripheral Neuropathy here: https://www.globalinsightservices.com/reports/chemotherapy-induced-peripheral-neuropathy-drug-pipeline-landscape/

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.